1. Short- and Midterm Comparison of Platelet-Rich Plasma with Hyaluronic Acid versus Leucocyte and Platelet-Rich Plasma on Pain and Function to Treat Hip Osteoarthritis. A Retrospective Study
- Author
-
Danilo Leonetti, Daniele Bruschetta, Roberto Restuccia, Paolo Rizzo, Maria Accorinti, Angelo Alito, Giorgio Basile, and Michelangelo Palco
- Subjects
gel ,PRP ,Polymers and Plastics ,Visual analogue scale ,Science ,degeneration ,Bioengineering ,General. Including alchemy ,Osteoarthritis ,Article ,Biomaterials ,chemistry.chemical_compound ,QD1-65 ,Hyaluronic acid ,L-PRP ,hyaluronic acid ,medicine ,Platelet ,pain ,cartilage ,L-PRP, PRP, cartilage, degeneration, gel, hyaluronic acid, osteoarthritis, pain ,QD1-999 ,QD146-197 ,osteoarthritis ,business.industry ,Organic Chemistry ,Repeated measures design ,Retrospective cohort study ,medicine.disease ,Chemistry ,chemistry ,Harris Hip Score ,Anesthesia ,Platelet-rich plasma ,business ,Inorganic chemistry - Abstract
Hip osteoarthritis (HOA) leads to pain and reduced function. The use of intra-articular injections based on corticosteroids, platelet-rich plasma (PRP), or hyaluronic acid (HA) is becoming a common symptomatic therapy for HOA. For the first time, we compare the effectiveness of plasma with a high concentration of platelets and leukocytes (L-PRP) with PRP+HA in patients with mild to moderate HOA. A total of 26 patients in each group were administered with either L-PRP or PRP+HA. Outcomes were evaluated at baseline, 3 months, and 1 year after the injection. The mean visual analog scale (VAS) and Harris hip score (HHS) within and between groups among different time points were compared using repeated measures ANCOVA (age set as a covariate). Both treatments were effective in reducing VAS, but not in significantly increasing HHS. In the group treated with L-PRP, VAS showed interaction between time and treatment (in favor of L-PRP). Pairwise comparison for treatment and time point evidenced a significant difference at 1-year follow-up between L-PRP and PRP-HA. Outcomes support the idea that both treatments may be effective in reducing pain, with maximal pain reduction achieved after 3 months. L-PRP showed better results in reducing VAS over time. Both treatments are effective at reducing pain in the short to medium term. L-PRP could be the treatment of choice due to a more marked effect over time. Nevertheless, further research is needed to better describe the clinical outcome of these formulations.
- Published
- 2021